, Volume 20, Issue 3, pp 129–143 | Cite as

A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activity

  • David B. Beck
  • T. Subramanian
  • S. Vijayalingam
  • Uthayashankar R. Ezekiel
  • Sandra Donkervoort
  • Michele L. Yang
  • Holly A. Dubbs
  • Xilma R. Ortiz-Gonzalez
  • Shenela Lakhani
  • Devorah Segal
  • Margaret Au
  • John M. GrahamJr
  • Sumit Verma
  • Darrel Waggoner
  • Marwan Shinawi
  • Carsten G. Bönnemann
  • Wendy K. ChungEmail author
  • G. ChinnaduraiEmail author
Original Article


We previously reported a pathogenic de novo p.R342W mutation in the transcriptional corepressor CTBP1 in four independent patients with neurodevelopmental disabilities [1]. Here, we report the clinical phenotypes of seven additional individuals with the same recurrent de novo CTBP1 mutation. Within this cohort, we identified consistent CtBP1-related phenotypes of intellectual disability, ataxia, hypotonia, and tooth enamel defects present in most patients. The R342W mutation in CtBP1 is located within a region implicated in a high affinity-binding cleft for CtBP-interacting proteins. Unbiased proteomic analysis demonstrated reduced interaction of several chromatin-modifying factors with the CtBP1 W342 mutant. Genome-wide transcriptome analysis in human glioblastoma cell lines expressing -CtBP1 R342 (wt) or W342 mutation revealed changes in the expression profiles of genes controlling multiple cellular processes. Patient-derived dermal fibroblasts were found to be more sensitive to apoptosis during acute glucose deprivation compared to controls. Glucose deprivation strongly activated the BH3-only pro-apoptotic gene NOXA, suggesting a link between enhanced cell death and NOXA expression in patient fibroblasts. Our results suggest that context-dependent relief of transcriptional repression of the CtBP1 mutant W342 allele may contribute to deregulation of apoptosis in target tissues of patients leading to neurodevelopmental phenotypes.


C-terminal binding protein CtBP1 Chromatin modifying complex Neurodevelopmental disease p.R342W mutation 



We thank the families for their generous contributions. We thank CureCMD and Anne Rutkowski with their help in patient recruitment.


This work was supported by an ICTS pilot grant from Washington University in St. Louis and Presidential Research support from Saint Louis University. This work was supported in part by grants from the JPB Foundation and the Simons Foundation. Work in C.G. Bönnemann’s laboratory is supported by intramural funds from the NIH National Institute of Neurological Disorders and Stroke. M.Y. is supported by the following industry sponsored research: Reveragen, Italfarmaco.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10048_2019_578_MOESM1_ESM.xlsx (75 kb)
Supplemental Figure 1 Proteomics analysis files. (XLSX 75 kb)


  1. 1.
    Beck DB, Cho MT, Millan F, Yates C, Hannibal M, O’Connor B, Shinawi M, Connolly AM, Waggoner D, Halbach S, Angle B, Sanders V, Shen Y, Retterer K, Begtrup A, Bai R, Chung WK (2016) A recurrent de novo CTBP1 mutation is associated with developmental delay, hypotonia, ataxia, and tooth enamel defects. Neurogenetics 17:173–178CrossRefGoogle Scholar
  2. 2.
    Boyd JM, Subramanian T, Schaeper U, la Regina M, Bayley S, Chinnadurai G (1993) A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J 12:469–478CrossRefGoogle Scholar
  3. 3.
    Schaeper U, Boyd JM, Verma S, Uhlmann E, Subramanian T, Chinnadurai G (1995) Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci U S A 92:10467–10471CrossRefGoogle Scholar
  4. 4.
    Chinnadurai G (2002) CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell 9:213–224CrossRefGoogle Scholar
  5. 5.
    Chinnadurai G (2007) Transcriptional regulation by C-terminal binding proteins. Int J Biochem Cell Biol 39:1593–1607CrossRefGoogle Scholar
  6. 6.
    Shi Y, Sawada JI, Sui G, Affar EB, Whetstine JR, Lan F, Ogawa H, Po-Shan Luke M, Nakatani Y, Shi Y (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422:735–738CrossRefGoogle Scholar
  7. 7.
    Fang M, Li J, Blauwkamp T, Bhambhani C, Campbell N, Cadigan KM (2006) C-terminal-binding protein directly activates and represses Wnt transcriptional targets in drosophila. EMBO J 25:2735–2745CrossRefGoogle Scholar
  8. 8.
    Itoh TQ, Matsumoto A, Tanimura T (2013) C-terminal binding protein (CtBP) activates the expression of E-box clock genes with CLOCK/CYCLE in drosophila. PLoS One 8:e63113CrossRefGoogle Scholar
  9. 9.
    Paliwal S, Ho N, Parker D, Grossman SR (2012) CtBP2 promotes human Cancer cell migration by transcriptional activation of Tiam1. Genes Cancer 3:481–490Google Scholar
  10. 10.
    Ray SK, Li HJ, Metzger E, Schule R, Leiter AB (2014) CtBP and associated LSD1 are required for transcriptional activation by NeuroD1 in gastrointestinal endocrine cells. Mol Cell Biol 34:2308–2317CrossRefGoogle Scholar
  11. 11.
    Bajpe PK et al (2013) The corepressor CTBP2 is a coactivator of RAR/RXR in retinoic acid signaling. Mol Cell Biol 33(16):3343–3353CrossRefGoogle Scholar
  12. 12.
    Bhambhani C, Chang JL, Akey DL, Cadigan KM (2011) The oligomeric state of CtBP determines its role as a transcriptional co-activator and co-repressor of wingless targets. EMBO J 30:2031–2043CrossRefGoogle Scholar
  13. 13.
    Madison DL, Wirz JA, Siess D, Lundblad JR (2013) Nicotinamide adenine dinucleotide-induced multimerization of the co-repressor CtBP1 relies on a switching tryptophan. J Biol Chem 288:27836–27848CrossRefGoogle Scholar
  14. 14.
    Bellesis AG, Jecrois AM, Hayes JA, Schiffer CA, Royer WE Jr (2018) Assembly of human C-terminal binding protein (CtBP) into tetramers. In: J biol Chem, vol 293, pp 9101–9112Google Scholar
  15. 15.
    Kuppuswamy M, Vijayalingam S, Zhao LJ, Zhou Y, Subramanian T, Ryerse J, Chinnadurai G (2008) Role of the PLDLS-binding cleft region of CtBP1 in recruitment of core and auxiliary components of the corepressor complex. Mol Cell Biol 28:269–281CrossRefGoogle Scholar
  16. 16.
    Nardini M, Spanò S, Cericola C, Pesce A, Massaro A, Millo E, Luini A, Corda D, Bolognesi M (2003) CtBP/BARS: a dual-function protein involved in transcription co-repression and Golgi membrane fission. EMBO J 22:3122–3130CrossRefGoogle Scholar
  17. 17.
    Kumar V, Carlson JE, Ohgi KA, Edwards TA, Rose DW, Escalante CR, Rosenfeld MG, Aggarwal AK (2002) Transcription corepressor CtBP is an NAD(+)-regulated dehydrogenase. Mol Cell 10:857–869CrossRefGoogle Scholar
  18. 18.
    Zhang Q, Piston DW, Goodman RH (2002) Regulation of corepressor function by nuclear NADH. Science 295:1895–1897Google Scholar
  19. 19.
    Hildebrand JD, Soriano P (2002) Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development. Mol Cell Biol 22:5296–5307CrossRefGoogle Scholar
  20. 20.
    Byun JS, Gardner K (2013) C-terminal binding protein: a molecular link between metabolic imbalance and epigenetic regulation in breast Cancer. Int J Cell Biol 2013:647975CrossRefGoogle Scholar
  21. 21.
    Dcona MM, Morris BL, Ellis KC, Grossman SR (2017) CtBP- an emerging oncogene and novel small molecule drug target: advances in the understanding of its oncogenic action and identification of therapeutic inhibitors. Cancer Biol Ther 18:379–391CrossRefGoogle Scholar
  22. 22.
    Sommerville EW, Alston CL, Pyle A, He L, Falkous G, Naismith K, Chinnery PF, McFarland R, Taylor RW (2017) De novo CTBP1 variant is associated with decreased mitochondrial respiratory chain activities. Neurol Gen 3:e187CrossRefGoogle Scholar
  23. 23.
    Nesvizhskii AI, Keller A, Kolker E, Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75:4646–4658CrossRefGoogle Scholar
  24. 24.
    da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57CrossRefGoogle Scholar
  25. 25.
    Zhao LJ, Kuppuswamy M, Vijayalingam S, Chinnadurai G (2009) Interaction of ZEB and histone deacetylase with the PLDLS-binding cleft region of monomeric C-terminal binding protein 2. BMC Mol Biol 10:89CrossRefGoogle Scholar
  26. 26.
    Grooteclaes ML, Frisch SM (2000) Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 19:3823–3828CrossRefGoogle Scholar
  27. 27.
    Kovi RC, Paliwal S, Pande S, Grossman SR (2010) An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ 17:513–521CrossRefGoogle Scholar
  28. 28.
    Lowman XH, McDonnell MA, Kosloske A, Odumade OA, Jenness C, Karim CB, Jemmerson R, Kelekar A (2010) The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol Cell 40:823–833CrossRefGoogle Scholar
  29. 29.
    Grooteclaes M, Deveraux Q, Hildebrand J, Zhang Q, Goodman RH, Frisch SM (2003) C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc Natl Acad Sci U S A 100:4568–4573CrossRefGoogle Scholar
  30. 30.
    Lek M et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • David B. Beck
    • 1
  • T. Subramanian
    • 2
  • S. Vijayalingam
    • 2
  • Uthayashankar R. Ezekiel
    • 3
  • Sandra Donkervoort
    • 4
  • Michele L. Yang
    • 5
  • Holly A. Dubbs
    • 6
  • Xilma R. Ortiz-Gonzalez
    • 7
  • Shenela Lakhani
    • 8
  • Devorah Segal
    • 9
  • Margaret Au
    • 10
  • John M. GrahamJr
    • 10
  • Sumit Verma
    • 11
  • Darrel Waggoner
    • 12
  • Marwan Shinawi
    • 13
  • Carsten G. Bönnemann
    • 4
  • Wendy K. Chung
    • 14
    Email author
  • G. Chinnadurai
    • 2
    Email author
  1. 1.National Human Genome Research InstituteNational Institutes of HealthBethesdaUSA
  2. 2.Institute for Molecular Virology, Department of Molecular Microbiology and ImmunologySaint Louis University School of MedicineSt. LouisUSA
  3. 3.Clinical Health SciencesSaint Louis UniversitySaint LouisUSA
  4. 4.National Institute of Neurological Disorders and Stroke Neurogenetics BranchNational Institutes of HealthBethesdaUSA
  5. 5.University of Colorado DenverAuroraUSA
  6. 6.Division of NeurologyThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  7. 7.Department of Neurology, Pereleman School of MedicineUniversity of Pennsylvania; Division of Neurology, The Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  8. 8.Center for Neurogenetics, Brain and Mind Research InstituteWeill Cornell MedicineNew YorkUSA
  9. 9.Department of Pediatrics, Division of Child NeurologyWeill Cornell MedicineNew YorkUSA
  10. 10.Medical Genetics, Department of PediatricsCedars-Sinai Medical CenterLos AngelesUSA
  11. 11.Division of Pediatric Neurology, Department of PediatricsEmory University School of MedicineAtlantaUSA
  12. 12.Department of Human GeneticsUniversity of ChicagoChicagoUSA
  13. 13.Department of Pediatrics, Division of Genetics and Genomic Medicine,Washington University School of MedicineSt. LouisUSA
  14. 14.Departments of Pediatrics and MedicineColumbia University Medical CenterNew YorkUSA

Personalised recommendations